Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

被引：2

作者：

Shadman, Mazyar ^{[1
]}

Salkar, Monika ^{[2
]}

Srivastava, Bhavini ^{[2
]}

Karve, Sudeep ^{[2
]}

Emond, Bruno ^{[3
]}

Gogna, Priyanka ^{[3
]}

Manceur, Ameur M. ^{[3
]}

Lafeuille, Marie-Helene ^{[3
]}

Rava, Andrew ^{[4
]}

Sun, Haiyan ^{[4
]}

Howarth, Amanda ^{[4
]}

Tomicki, Samantha ^{[4
]}

Agatep, Barnabie ^{[5
]}

Jones, Barton ^{[5
]}

Franceschini, Erin ^{[2
]}

Saifan, Chadi ^{[2
]}

Bacchus, Shaffee ^{[2
]}

Roeker, Lindsey ^{[6
]}

Stephens, Deborah M. ^{[7
]}

机构：

[1] Fred Hutchinson Canc Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA

[2] AbbVie, N Chicago, IL USA

[3] Anal Grp Inc, Montreal, PQ, Canada

[4] Genesis Res Grp, Hoboken, NJ USA

[5] Inovalon, Bowie, MD USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Univ N Carolina, Div Hematol, Chapel Hill, NC USA

来源：

LEUKEMIA & LYMPHOMA | 2024年

基金：

美国国家卫生研究院;

关键词：

Chronic lymphocytic leukemia; ibrutinib; real-world evidence; dose reduction; DOSING PATTERNS; THERAPY; CLL;

D O I：

10.1080/10428194.2024.2402814

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study used real-world data from three separate United States (US) databases to evaluate dosing patterns and time to next treatment (TTNT) following the first-incident adverse event (AE) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with first-line ibrutinib with and without dose reduction (DR). Median TTNT or death in patients with and without a DR following an AE in each database was as follows: Optum Clinformatics Data Mart (CDM): 59.5 and 30.6 months; ConcertAI: 27.1 and 18.0 months; and Medicare Fee-for-Service (FFS): 49.8 and 22.0 months, respectively. Median TTNT or death in patients with cardiac AEs, with and without a DR, was: Optum CDM: 44.4 and 22.9 months; ConcertAI: 29.9 and 18.3 months; and Medicare FFS: 49.6 and 14.0 months, respectively. Ibrutinib DR was associated with fewer outpatient visits and lower CLL/SLL-related medical costs. These findings suggest that utilizing ibrutinib DR may effectively manage tolerability without compromising clinical efficacy.

引用

页数：10

共 50 条

[41] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
Wang, Ruibin
Ding, Zhijie
Lu, Xiaoxiao
Mavani, Heena
He, Jinghua
Qureshi, Zaina P.
Pinilla-Ibarz, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients
Lin, Kevin H.
Huynh, Lynn
Yang, Xiaoqin
Zanardo, Enrico
Lema, Neema
Matay, Lisa
Balasubramanian, Sobana
Liborski, Daria
McDonough, Mikaela
Foreman, Jillian
Farooqui, Mohammed Z. H.
De Nigris, Enrico
Gandra, Shravanthi R.
Sarpong, Eric M.
Duh, Mei Sheng
Brown, Jennifer R.
Davids, Matthew Steven
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
Muta, Tsuyoshi
Masamoto, Yosuke
Yamamoto, Go
Kurahashi, Shingo
Kameoka, Yoshihiro
Ota, Shuichi
Matsuki, Eri
Ozeki, Kazutaka
Toyama, Takanori
Takahashi, Naoki
Kumode, Takahiro
Aotsuka, Nobuyuki
Yoshimura, Takuro
Tamura, Hideto
Omi, Ai
Shibayama, Kazuhiro
Watanabe, Aki
Isobe, Yasushi
Kojima, Kensuke
Takizawa, Jun
Nagai, Hirokazu
Suzumiya, Junji
Aoki, Sadao
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, : 161 - 173
[44] Real-World Incidence and Management of Ibrutinib-Induced Hypertension in Patients with Chronic Lymphocytic Leukemia
Gleaton, Ashley Mariah
Loop, Matthew Shane
Coombs, Catherine C.
Rodgers, Jo E.
Muluneh, Benyam
BLOOD, 2022, 140 : 13230 - 13231
[45] Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Narezkina, Anna
Akhter, Nausheen
Lu, Xiaoxiao
Emond, Bruno
Huang, Qing
Panjabi, Sumeet
Hilts, Annalise
Lu, Stephanie
Lafeuille, Helene
Lafeuille, Marie-Helene
Choi, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S276 - S277
[46] Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis
Kittai, Adam S.
Hang, Ying
Bhat, Seema A.
Clark, Abi
Grever, Michael
Rhodes, Joanna M.
Roberts, Melyssa
Rogers, Kerry A.
Teschemaker, Anna
Munoz-Sagastibelza, Maria
Woyach, Jennifer A.
Barrientos, Jacqueline C.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (04) : 780 - 784
[47] Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status
De Nigris, Enrico
Huntington, Scott F.
Puckett, Justin
Kamal-Bahl, Sachin
Farooqui, Mohammed Z. H.
Ryland, Katherine Elizabeth
Sarpong, Eric
Yang, Xiaoqin
Doshi, Jalpa
BLOOD, 2022, 140 : 5043 - 5044
[48] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
Huang, Qing
Deering, Kathleen L.
Harshaw, Qing
Leslie, Lori A.
ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
[49] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
Qing Huang
Kathleen L. Deering
Qing Harshaw
Lori A. Leslie
Advances in Therapy, 2022, 39 : 3292 - 3307
[50] Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study
Yang, Xiaoqin
Zanardo, Enrico
Lejeune, Dominique
De Nigris, Enrico
Sarpong, Eric
Farooqui, Mohammed Z. H.
Donzella, Sidney M.
Laliberte, Francois
BLOOD, 2022, 140 : 10932 - 10933

← 1 2 3 4 5 →